This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tassone, P. Articles by Munshi, N. C. Search for Related Content PubMed PubMed Citation Articles by Tassone, P. Articles by Munshi, N. C.

In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N^2'-Deacetyl-N^2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56⁺ Multiple Myeloma Cells

¹ Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and ² VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts; ³ University of "Magna Græcia", Catanzaro, Italy; and ⁴ ImmunoGen, Inc., Cambridge, Massachusetts

HuN901 is a humanized monoclonal antibody that binds with high affinity to CD56, the neuronal cell adhesion molecule. HuN901 conjugated with the maytansinoid N^2'-deacetyl-N^2'-(3-mercapto-1-oxopropyl)-maytansine (DM1), a potent antimicrotubular cytotoxic agent, may provide targeted delivery of the drug to CD56 expressing tumors. Based on gene expression profiles of primary multiple myeloma (MM) cells showing expression of CD56 in 10 out of 15 patients (66.6%) and flow cytometric profiles of MM (CD38^brightCD45^lo) cells showing CD56 expression in 22 out of 28 patients (79%), we assessed the efficacy of huN901-DM1 for the treatment of MM. We first examined the in vitro cytotoxicity and specificity of huN901-DM1 on a panel of CD56⁺ and CD56^– MM cell lines, as well as a CD56^– Waldenstrom’s macroglobulinemia cell line. HuN901-DM1 treatment selectively decreased survival of CD56⁺ MM cell lines and depleted CD56⁺ MM cells from mixed cultures with a CD56^– cell line or adherent bone marrow stromal cells. In vivo antitumor activity of huN901-DM1 was then studied in a tumor xenograft model using a CD56⁺ OPM2 human MM cell line in SCID mice. We observed inhibition of serum paraprotein secretion, inhibition of tumor growth, and increase in survival of mice treated with huN901-DM1. Our data therefore demonstrate that huN901-DM1 has significant in vitro and in vivo antimyeloma activity at doses that are well tolerated in a murine model. Taken together, these data provide the framework for clinical trials of this agent to improve patient outcome in MM.

This article has been cited by other articles:

				F. van Rhee, S. M. Szmania, M. Dillon, A. M. van Abbema, X. Li, M. K. Stone, T. K. Garg, J. Shi, A. M. Moreno-Bost, R. Yun, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Mol. Cancer Ther., September 1, 2009; 8(9): 2616 - 2624. [Abstract] [Full Text] [PDF]

				H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037. [Abstract] [Full Text] [PDF]

				A. G. Polson and M. X. Sliwkowski Toward an Effective Targeted Chemotherapy for Multiple Myeloma Clin. Cancer Res., June 15, 2009; 15(12): 3906 - 3907. [Abstract] [Full Text] [PDF]

				C. P. Leamon, J. A. Reddy, M. Vetzel, R. Dorton, E. Westrick, N. Parker, Y. Wang, and I. Vlahov Folate Targeting Enables Durable and Specific Antitumor Responses from a Therapeutically Null Tubulysin B Analogue Cancer Res., December 1, 2008; 68(23): 9839 - 9844. [Abstract] [Full Text] [PDF]

				Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood, August 15, 2008; 112(4): 1329 - 1337. [Abstract] [Full Text] [PDF]

				B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]

				J. A. Reddy, E. Westrick, H. K.R. Santhapuram, S. J. Howard, M. L. Miller, M. Vetzel, I. Vlahov, R. V.J. Chari, V. S. Goldmacher, and C. P. Leamon Folate Receptor-Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate Cancer Res., July 1, 2007; 67(13): 6376 - 6382. [Abstract] [Full Text] [PDF]

				C. D. Austin, X. Wen, L. Gazzard, C. Nelson, R. H. Scheller, and S. J. Scales Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates PNAS, December 13, 2005; 102(50): 17987 - 17992. [Abstract] [Full Text] [PDF]

				T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]

				P. Tassone, P. Neri, J. L. Kutok, O. Tournilhac, D. D. Santos, E. Hatjiharissi, V. Munshi, S. Venuta, K. C. Anderson, S. P. Treon, et al. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia Blood, August 15, 2005; 106(4): 1341 - 1345. [Abstract] [Full Text] [PDF]

				P. Tassone, P. Neri, R. Burger, R. Savino, M. Shammas, L. Catley, K. Podar, D. Chauhan, S. Masciari, A. Gozzini, et al. Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma Clin. Cancer Res., June 1, 2005; 11(11): 4251 - 4258. [Abstract] [Full Text] [PDF]

				P. Tassone, V. S. Goldmacher, P. Neri, A. Gozzini, M. A. Shammas, K. R. Whiteman, L. L. Hylander-Gans, D. R. Carrasco, T. Hideshima, R. Shringarpure, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells Blood, December 1, 2004; 104(12): 3688 - 3696. [Abstract] [Full Text] [PDF]